This is Local London | Obinutuzumab Tops Rituximab in CLL Trial Cancer Network Obinutuzumab topped rituximab in a large chronic lymphocytic leukemia (CLL) trial of older, newly diagnosed patients, demonstrating improvements in response rate and progression-free survival (PFS), according to results presented at the 2013 American ... Obinutuzumab routs rituximab in older chronic lymphocytic leukemia patients Dr. Goede on Obinutuzumab Versus Rituximab in CLL New Drug Combo Potentially 'Practice Changing' in CLL |
